HOOKIPA Pharma (HOOK) announced the appointment of Director Julie O’Neill as Non-Executive Chair of the Company’s Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab (GMAB). The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Hookipa Pharma price target raised to $24 from $23 at JMP Securities
- Hookipa Pharma reports Q2 EPS ($1.52), consensus ($1.25)
- HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Hookipa Pharma Announces Executive Reshuffle and Board Enhancements